fluxd
.news
Arcus Biosciences discontinues lung cancer study due to futility · fluxd.news
fluxd
.news
LIVE
☽
Terms
Privacy
Cookies
☰
Back to Feed
Fintech
Arcus Biosciences discontinues lung cancer study due to futility
Investing
·
April 20, 2026 at 12:05 PM
Original Source
Investing — www.investing.com
Share
Related in Fintech
Amazon, Anthropic Deepen AI Partnership
PYMNTS
Commercial Loans Show US Economy Defies Forecasts
PYMNTS
Zenskar Raises $15 Million for Agentic AI
PYMNTS
Apple Hardware Leader John Ternus to Succeed CEO
PYMNTS